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Background: Radiotherapy plays an important role in the treatment of Hodgkin lymphoma (HL). However, long term survivors treated 
with mediastinal RT have an increased risk for the development of cardiovascular disease and secondary cancers. Efforts have been 
made to reduce the rates of late toxicity and promising results have been published with intensity modulated radiation therapy (IMRT) 
and deep inspiration breath-hold (DIBH). Patients with HL are often young with good respiratory function, enabling the use of DIBH.
Objective: To evaluate the potential benefit of combining IMRT with DIBH to decrease cardiac and lung dose in mediastinal RT.
Material & Methods: Three patients with cervical and mediastinal lymphoma involvement received involved site radiotherapy (ISRT) 
with 30 Gy in 15 fractions. Each patient underwent a planning CT scan in free-breathing (FB) and DIBH using a 5 point thermoplastic 
mask. IMRT plans for FB and DIBH were created and compared with respect to PTV coverage and doses to organs at risk.
Results: Patient 1 had a large PTV volume extending downwards into the anterior mediastinum reaching the cardiofrenic space while 
patients 2 and 3 had disease only on the upper mediastinum. Mean heart dose was lower with DIBH in all patients (~22-52%). Greater 
lung expansion was achieved with DIBH which contributed to lower mean lung doses (~14-18%) and lung V20 (~20-28%). Higher 
absolute decreases on mean heart and lung doses were seen on patient 1. PTV coverage (D95, V95) was similar for both plans in all 
patients. DIBH-IMRT was chosen for treatment delivery on patients 1 and 2.
Discussion: Significant decreases on heart and lung doses can be achieved while not comprising PTV coverage. Patient anatomy and 
disease extension will determine the degree of dosimetric improvement when using DIBH. Also, appropriate patient compliance is 
essential to perform DIBH.
Conclusion: Combining DIBH and IMRT can significantly improve doses on heart and lung when using mediastinal RT and thus reduce 
long-term morbidity. Choice between treatment delivery techniques should be made on an individualized basis.
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